Literature DB >> 20180761

AMPK activators as novel therapeutics for type 2 diabetes.

Li-Fang Yu1, Bei-Ying Qiu, Fa-Jun Nan, Jia Li.   

Abstract

AMPK is a potential target of metabolic diseases including obesity and type 2 diabetes. The activation of AMPK can lead to an increase of glucose uptake into muscle, decreased gluconeogenesis in liver, increased fatty acid oxidation in muscle and liver, decreased fatty acid synthesis in liver and adipose tissue, and increase mitochondrial biogenesis. Until now, many efforts from industrial and academia have been focused on searching novel agents that activate AMPK directly or indirectly. This review will discuss recent advances in the search for novel therapeutic agents that mediate their activity via AMPK activation.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20180761     DOI： 10.2174/156802610790980611

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN： 1568-0266            Impact factor:   3.295


  9 in total

Review 1.  Recent advances in understanding the anti-diabetic actions of dietary flavonoids.

Authors:  Pon Velayutham Anandh Babu; Dongmin Liu; Elizabeth R Gilbert
Journal:  J Nutr Biochem       Date:  2013-09-09       Impact factor: 6.048

2.  AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity.

Authors:  Guifen He; Yi-Wei Zhang; Jun-Ho Lee; Shelya X Zeng; Yunyuan V Wang; Zhijun Luo; X Charlie Dong; Benoit Viollet; Geoffrey M Wahl; Hua Lu
Journal:  Mol Cell Biol       Date:  2013-11-04       Impact factor: 4.272

3.  AMP-activated protein kinase as regulator of P2Y(6) receptor-induced insulin secretion in mouse pancreatic β-cells.

Authors:  Ramachandran Balasubramanian; Hiroshi Maruoka; P Suresh Jayasekara; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2013-01-17       Impact factor: 5.858

4.  Danthron activates AMP-activated protein kinase and regulates lipid and glucose metabolism in vitro.

Authors:  Rong Zhou; Ling Wang; Xing Xu; Jing Chen; Li-hong Hu; Li-li Chen; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

5.  Mitochondrial roles and cytoprotection in chronic liver injury.

Authors:  Davide Degli Esposti; Jocelyne Hamelin; Nelly Bosselut; Raphaël Saffroy; Mylène Sebagh; Alban Pommier; Cécile Martel; Antoinette Lemoine
Journal:  Biochem Res Int       Date:  2012-06-15

Review 6.  Could gestational diabetes mellitus be managed through dietary bioactive compounds? Current knowledge and future perspectives.

Authors:  Carmela Santangelo; Alessandra Zicari; Elisabetta Mandosi; Beatrice Scazzocchio; Emanuela Mari; Susanna Morano; Roberta Masella
Journal:  Br J Nutr       Date:  2016-02-16       Impact factor: 3.718

7.  Ampelopsin Improves Insulin Resistance by Activating PPARγ and Subsequently Up-Regulating FGF21-AMPK Signaling Pathway.

Authors:  Yong Zhou; Ying Wu; Yu Qin; Lei Liu; Jing Wan; Lingyun Zou; Qianyong Zhang; Jundong Zhu; Mantian Mi
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

8.  Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver.

Authors:  Miguel A Lanaspa; Christina Cicerchi; Gabriela Garcia; Nanxing Li; Carlos A Roncal-Jimenez; Christopher J Rivard; Brandi Hunter; Ana Andrés-Hernando; Takuji Ishimoto; Laura G Sánchez-Lozada; Jeffrey Thomas; Robert S Hodges; Colin T Mant; Richard J Johnson
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

9.  Air pollution-mediated susceptibility to inflammation and insulin resistance: influence of CCR2 pathways in mice.

Authors:  Cuiqing Liu; Xiaohua Xu; Yuntao Bai; Tse-Yao Wang; Xiaoquan Rao; Aixia Wang; Lixian Sun; Zhekang Ying; Liubov Gushchina; Andrei Maiseyeu; Masako Morishita; Qinghua Sun; Jack R Harkema; Sanjay Rajagopalan
Journal:  Environ Health Perspect       Date:  2013-10-22       Impact factor: 9.031
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.